INTECH Investment Management’s Vaxcyte PCVX Stock Holding History

INTECH Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.66M	Sell	28,577 -2,636	-8%	-$143K	0.02%	785
2026 Q1	$1.81M	Sell	31,213 -27,021	-46%	-$1.47M	0.02%	743
2025 Q4	$2.69M	Sell	58,234 -9,722	-14%	-$435K	0.02%	603
2025 Q3	$2.45M	Sell	67,956 -1,813	-3%	-$60.1K	0.02%	667
2025 Q2	$2.27M	Sell	69,769 -19,443	-22%	-$637K	0.02%	686
2025 Q1	$3.37M	Buy	89,212 +27,384	+44%	+$2.19M	0.03%	471
2024 Q4	$5.06M	Buy	61,828 +33,600	+119%	+$3.34M	0.05%	319
2024 Q3	$3.23M	Buy	+28,228	New	+$2.54M	0.04%	356

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

INTECH Investment Management's PCVX Position: Q2 2026 in Review

INTECH Investment Management reduced its Vaxcyte (PCVX) stake by 8.4% in Q2 2026, selling an estimated $143K and leaving 28,577 shares worth $1.66M. The position accounts for 0.02% of the portfolio, ranked #785.

INTECH Investment Management first reported a position in PCVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.06M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

INTECH Investment Management held 28,577 shares of Vaxcyte worth $1.66M as of Q2 2026.
INTECH Investment Management sold 2,636 Vaxcyte shares in Q2 2026, an estimated $143K.
Vaxcyte made up 0.02% of INTECH Investment Management's portfolio in Q2 2026, its #785 holding.
INTECH Investment Management first reported a position in Vaxcyte in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Vaxcyte position peaked at $5.06M in Q4 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.